1. Hu, Qingjiang, Masuda, Takaaki, Sato, Kuniaki, Maehara, Yoshihiko, Mimori, Koshi. 2017. Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer. In Annals of surgical oncology, 25, 745-753. doi:10.1245/s10434-017-6292-6. https://pubmed.ncbi.nlm.nih.gov/29270876/
2. Kanai, Ryo, Uehara, Takeshi, Yoshizawa, Takahiro, Nagaya, Tadanobu, Ota, Hiroyoshi. 2023. ARL4C is associated with epithelial-to-mesenchymal transition in colorectal cancer. In BMC cancer, 23, 478. doi:10.1186/s12885-023-10958-4. https://pubmed.ncbi.nlm.nih.gov/37237373/
3. Sun, Yipeng, Zhang, Zhuhua, Xiang, Fenfen, Ni, Zhenhua, Wang, Xiongbiao. 2020. Decreasing Arl4c expression by inhibition of AKT signal in human lung adenocarcinoma cells. In Life sciences, 246, 117428. doi:10.1016/j.lfs.2020.117428. https://pubmed.ncbi.nlm.nih.gov/32057901/
4. Chen, Qian, Weng, Hai-Yan, Tang, Xiao-Peng, Bian, Xiu-Wu, Yao, Xiao-Hong. 2018. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma. In The Journal of pathology, 247, 266-278. doi:10.1002/path.5189. https://pubmed.ncbi.nlm.nih.gov/30357833/